Abstract: An exhaust gas purifying catalyst 1 has a catalyst substrate 3 and catalyst coating layers 5, 7 that are formed on the catalyst substrate 3 and contain (a) Rh, (b) Pt, (c) an alkali metal or alkaline earth element, and (d) an inorganic oxide. The catalyst coating layers 5, 7 has a layered structure including an inside layer 5 where the component (a) is substantially locally existing, and an outside layer 7 where the component (b) is substantially locally existing. The inside layer 5 also contains a zirconia oxide.

Abstract: The present invention provides an exhaust gas purification catalyst which has a structure which prevents competitive adsorption of HC, CO, and NOx and enables effective utilization of an NOx storage reduction type catalyst. The exhaust gas purification catalyst of the present invention is characterized by having an NOx storage reduction type catalyst layer which contains at least one type of NOx storage material which is selected from an alkali metal or an alkali earth metal and Pt and/or Rh on a substrate and having an oxidation catalyst layer which carries Pt and/or Pd on the NOx storage reduction type catalyst layer.

Abstract: Disclosed is an exhaust gas purifying catalyst, including Rh/Y—ZrO2 particles obtained by supporting Rh on zirconia support particles which contain yttria, wherein yttria is contained in an amount of 2˜9 mol % in the support particles. The exhaust gas purifying catalyst exhibits a superior high-temperature durability because the zirconia support can resist heat, thereby particularly increasing the structure retaining power and the thermal stability of Rh.

Abstract: An upstream catalyst and a downstream catalyst are arranged in series and are housed in a common casing disposed in an engine exhaust passage. The upstream catalyst including a NOx storage-reduction catalyst that adsorbs NOx contained in incoming exhaust gas when the air-fuel ratio of the incoming exhaust gas is lean, and releases and reduces the adsorbed NOx when the air-fuel ratio of the incoming exhaust gas becomes rich, and the downstream catalyst includes a three-way catalyst. The upstream catalyst has a higher oxidizing capability than the downstream catalyst, and the downstream catalyst has a higher reducing capability than the upstream catalyst. The upstream catalyst has a multi-layer structure including an upper layer and a lower layer, and is prepared such that the upper layer has a higher oxidizing capability than the lower layer, and the lower layer has a higher reducing capability than the upper layer.

Abstract: The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30, etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.

Abstract: An exhaust gas purifying catalyst 1 has a catalyst substrate 3 and catalyst coating layers 5, 7 that are formed on the catalyst substrate 3 and contain (a) Rh, (b) Pt, (c) an alkali metal or alkaline earth element, and (d) an inorganic oxide. The catalyst coating layers 5, 7 has a layered structure including an inside layer 5 where the component (a) is substantially locally existing, and an outside layer 7 where the component (b) is substantially locally existing. The inside layer 5 also contains a zirconia oxide.

Abstract: The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30 etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.

Abstract: The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30, etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.

Abstract: The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-N-sulfonylaminocyclopropane compound of formula (1) wherein R1 is —W-A1-W1-A2, W is —(CH2)m—X—(CH2)n—, wherein W1 is —(CH2)m1—X1—(CH2)n1—, m, m1, n and n1 are the same or different and each is 0 to 6, X and X1 are the same or different and each is a single bond, etc., A1 is an optionally substituted C3-14 hydrocarbon ring group, etc. and A2 is a substituted C3-14 hydrocarbon ring group etc.; R2 is —(CH2)r—CO—R8, etc., wherein r is 0 to 6 and R8 is a C1-6 alkoxy group, etc.; R3 and R4 are the same or different and each is a hydrogen atom, a C1-6 alkyl group, etc.; and R5 is —CO2R21, etc.; R30 and R31 are the same or different and each is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30, etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.

Abstract: The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X1 is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1-(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30, etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.

Abstract: The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-N-sulfonylaminocyclopropane compound of formula (1): wherein R1 is —W-A1—W1-A2, W is —(CH2)m—X—(CH2)n—, wherein W1 is —(CH2)m1—X1—(CH2)n1—, m, m1, n and n1 are the same or different and each is 0 to 6, X and X1 are the same or different and each is a single bond, etc., A1 is an optionally substituted C3-14 hydrocarbon ring group, etc. and A2 is a substituted C3-14 hydrocarbon ring group etc.; R2 is —(CH2)r—CO—R8, etc., wherein r is 0 to 6 and R8 is a C1-6 alkoxy group, etc.; R3 and R4 are the same or different and each is a hydrogen atom, a C1-6 alkyl group, etc.; and R5 is —CO2R21 etc.; R30 and R31 are the same or different and each is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

Abstract: Flexographic printing press for printing on the corrugated board sheets passing between the printing cylinder provided with a form plate on its peripheral surface and the receiving roll. Flexographic ink stored between a doctor roll and an anilox roll, which are rotated in the opposite directions as these rolls contact each other, is supplied to said form plate via said anilox roll to thereby carry out a printing operation. Said anilox roll is driven by said printing cylinder at same peripheral speed. Said doctor roll is driven by a speed change drive mechanism for reducing the peripheral speed of said doctor roll when the rotational speed of said anilox roll is increased, and increasing the peripheral speed of said doctor roll when the rotational speed of said anilox roll is decreased.

Abstract: There is provided a rotary die cutter for effecting a punching and scribing on a sheet which is fed between a die cylinder and an anvil cylinder disposed in parallel with said die cylinder. The die cylinder is adapted to be rotated in a predetermined direction and provided on its peripheral surface with a knife and a scribing rule. The anvil cylinder is adapted to be rotated in the opposite direction to the die cylinder and provided on its peripheral surface with an anvil for receiving the knife and the scribing rule. There is a mechanism for adjusting the clearance between the die cylinder and the anvil cylinder. A blade carrier is disposed adjacent to the anvil cylinder and slidable in the axial direction of the anvil cylinder. A cutting blade capable of cutting the anvil surface is attached to the blade carrier in such a manner as to move toward and away from the axis of the anvil cylinder.

Abstract: A device for counting and delivering sheets which accumulates a plurality of paste-applied and folded cardboard sheets, delivered by a paste-applying and folding machine, in a hopper for delivery to a next step in batches of a prescribed number of sheets. A counter is employed to count the individual sheets as they are being accumulated in the hopper for further processing. A plurality of ledges reciprocal in a vertical direction and projectable into the sheets being accumulated in the hopper divide the sheets into batches of the prescribed number as a function of the sheets having been counted. The batches are then removed from the hopper and delivered to a binding machine which is adapted to bind the cardboard sheets as a next step.

Abstract: A scrap knockout for use with a rotary punching apparatus includes a knife cylinder equipped with punch blades on the outer peripheral surface, and an anvil cylinder having a layer against which the blades are pressed, so as to punch a workpiece fed in between the two rotating cylinders. The scrap knockout is so arranged that each of the punch blades is formed with a cut or slot, and a scrap knockout lever is engaged with the cut or slot so as to be restricted in its upward and downward movements, with one end of the knockout lever is a free end located in the space surrounded by the punch blade and the other end is pivotally held by a punch blade support, so that the scrap formed by the punching can be removed by the upward motion of the lever.